Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 88 entries
View as:

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03568422 Org: User:
Start: 02/05/19 End: 12/31/25 Due: 12/31/26

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00819208 Org: User:
Start: 06/02/09 End: 12/15/30 Due: 12/15/31

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03624543 Org: User:
Start: 02/14/19 End: 12/31/25 Due: 12/31/26

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05743777 Org: User:
Start: 05/12/23 End: 05/12/23 Due: 05/12/24

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Phase: N/A Priority: Normal
NCT ID: NCT02879162 Org: User:
Start: 12/14/16 End: 01/29/25 Due: 01/29/26

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03768570 Org: User:
Start: 10/25/19 End: 03/31/26 Due: 03/31/27

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04176848 Org: User:
Start: 08/10/20 End: 06/30/25 Due: 06/30/26

Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03784755 Org: User:
Start: 11/15/19 End: 07/30/27 Due: 07/30/28

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

Phase: N/A Priority: Normal
NCT ID: NCT02033993 Org: User:
Start: 03/11/14 End: 10/28/20 Due: 10/28/21

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT02974803 Org: User:
Start: 02/09/18 End: 07/29/20 Due: 07/29/21

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05714891 Org: User:
Start: 09/15/23 End: 03/31/28 Due: 03/31/29

A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01656538 Org: User:
Start: 02/20/13 End: 02/14/18 Due: 02/14/19

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02436707 Org: User:
Start: 10/27/15 End: 12/31/26 Due: 12/31/27

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02870920 Org: User:
Start: 10/12/16 End: 06/07/22 Due: 06/07/23

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Phase: N/A Priority: Normal
NCT ID: NCT03410615 Org: User:
Start: 05/28/18 End: 07/31/26 Due: 07/31/27

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04918186 Org: User:
Start: 05/03/22 End: 12/31/25 Due: 12/31/26

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

Phase: N/A Priority: Normal
NCT ID: NCT05371808 Org: User:
Start: 01/27/23 End: 10/01/28 Due: 10/01/29

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04161248 Org: User:
Start: 09/02/20 End: 07/31/26 Due: 07/31/27

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05451004 Org: User:
Start: 02/10/23 End: 08/30/31 Due: 08/30/32

Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02905318 Org: User:
Start: 07/04/17 End: 12/30/25 Due: 12/30/26

De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03822897 Org: User:
Start: 06/28/19 End: 06/30/25 Due: 06/30/26

Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

Phase: N/A Priority: Normal
NCT ID: NCT03461952 Org: User:
Start: 03/11/19 End: 02/09/22 Due: 02/09/23

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT02285816 Org: User:
Start: 01/22/15 End: 12/31/25 Due: 12/31/26

Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02960087 Org: User:
Start: 03/06/17 End: 10/30/29 Due: 10/30/30

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase: N/A Priority: Normal
NCT ID: NCT03385655 Org: User:
Start: 08/01/18 End: 12/31/25 Due: 12/31/26